Mechanistic Evaluation of a Novel Small Molecule Targeting Mitochondria in Pancreatic Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Shabaik, Yumna H ^a   Millard, Melissa ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; ERLOTINIB; FOCAL ADHESION KINASE; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P62; REACTIVE OXYGEN METABOLITE; TP 421; TRIPHENYLPHOSPHINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL ADHESION; CELL MIGRATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; IC 50; MITOCHONDRION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DRUG DISCOVERY; FLUORESCENCE; HUMANS; INHIBITORY CONCENTRATION 50; MITOCHONDRIA; ORGANOPHOSPHORUS COMPOUNDS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84872659439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054346     Document Type: Article

References (69)

1. ACS (2012) Cancer Facts & Figures 2012. Atlanta: American Cancer Society.
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
3. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, et al. (2007) Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 21: 1696-1706; discussion 1706-1699, 1712, 1715.
4. Plunkett W, Huang P, Gandhi V, (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6Suppl 6: 7-13.
5. Conradt L, Godl K, Schaab C, Tebbe A, Eser S, et al. (2011) Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 13: 1026-1034.
6. Hung SW, Mody HR, Govindarajan R, (2012) Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 320: 138-149.
7. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, et al. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500-503.
8. Hruban RH, Goggins M, Parsons J, Kern SE, (2000) Progression model for pancreatic cancer. Clin Cancer Res 6: 2969-2972.
9. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA, (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
10. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25: 717-729.
11. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, et al. (2011) Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 25: 460-470.
12. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, et al. (2008) Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci 99: 1813-1819.
13. Gogvadze V, (2011) Targeting mitochondria in fighting cancer. Curr Pharm Des 17: 4034-4046.
14. Fulda S, Kroemer G, (2011) Mitochondria as therapeutic targets for the treatment of malignant disease. Antioxid Redox Signal 15: 2937-2949.
15. Modica-Napolitano JS, Aprille JR, (2001) Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49: 63-70.
16. Burns RJ, Smith RA, Murphy MP, (1995) Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix. Arch Biochem Biophys 322: 60-68.
17. Biswas S, Dodwadkar NS, Piroyan A, Torchilin VP, (2012) Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials 33: 4773-4782.
18. Cocheme HM, Kelso GF, James AM, Ross MF, Trnka J, et al. (2007) Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion 7Suppl: S94-102.
19. Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, et al. (2008) Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med Chem Lett 18: 5594-5597.
20. Dong LF, Jameson VJ, Tilly D, Prochazka L, Rohlena J, et al. (2011) Mitochondrial targeting of alpha-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. Free Radic Biol Med 50: 1546-1555.
21. Rohlena J, Dong LF, Kluckova K, Zobalova R, Goodwin J, et al. (2011) Mitochondrially targeted alpha-tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healing. Antioxid Redox Signal 15: 2923-2935.
22. Dong LF, Jameson VJ, Tilly D, Cerny J, Mahdavian E, et al. (2011) Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem 286: 3717-3728.
23. Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, et al. (2011) The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 32: 5673-5687.
24. Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP, (2012) Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release 159: 393-402.
25. Malhi SS, Budhiraja A, Arora S, Chaudhari KR, Nepali K, et al. (2012) Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. Int J Pharm 432: 63-74.
26. Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, et al. (2010) Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. PLoS One 5.
27. Murphy MP, (2008) Targeting lipophilic cations to mitochondria. Biochim Biophys Acta 1777: 1028-1031.
28. Sou YS, Waguri S, Iwata J, Ueno T, Fujimura T, et al. (2008) The Atg8 conjugation system is indispensable for proper development of autophagic isolation membranes in mice. Mol Biol Cell 19: 4762-4775.
29. Bartz RR, Piantadosi CA, (2010) Clinical review: oxygen as a signaling molecule. Crit Care 14: 234.
30. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, et al. (2011) Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways? J Signal Transduct 2011: 792639.
31. Galli S, Antico Arciuch VG, Poderoso C, Converso DP, Zhou Q, et al. (2008) Tumor cell phenotype is sustained by selective MAPK oxidation in mitochondria. PLoS One 3: e2379.
32. Zhuang S, Schnellmann RG, (2006) A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319: 991-997.
33. Cleaver JE, (2011) gammaH2Ax: biomarker of damage or functional participant in DNA repair "all that glitters is not gold!". Photochem Photobiol 87: 1230-1239.
34. Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R, (2010) Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 10: 1647-1661.
35. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
36. Lim ST, Mikolon D, Stupack DG, Schlaepfer DD, (2008) FERM control of FAK function: implications for cancer therapy. Cell Cycle 7: 2306-2314.
37. Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB, (2010) Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 9: 2322-2332.
38. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, et al. (2009) A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 8: 2435-2443.
39. Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, et al. (2007) Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10: 167-182.
40. Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, et al. (2012) Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol 47: 203-213.
41. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, et al. (2008) Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27: 6322-6333.
42. Madar I, Ravert H, Nelkin B, Abro M, Pomper M, et al. (2007) Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging 34: 2057-2065.
43. Murphy MP, Smith RA, (2007) Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656.
44. Brand MD, (2010) The sites and topology of mitochondrial superoxide production. Exp Gerontol 45: 466-472.
45. Oberley LW, Oberley TD, (1988) Role of antioxidant enzymes in cell immortalization and transformation. Mol Cell Biochem 84: 147-153.
46. Oberley LW, Buettner GR, (1979) Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141-1149.
47. Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, et al. (2003) The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res 63: 1297-1303.
48. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD, (2008) Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270.
49. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, et al. (2011) Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10: 37.
50. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, et al. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109.
51. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M, (1994) Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58: 185-191.
52. Madesh M, Zong WX, Hawkins BJ, Ramasamy S, Venkatachalam T, et al. (2009) Execution of superoxide-induced cell death by the proapoptotic Bcl-2-related proteins Bid and Bak. Mol Cell Biol 29: 3099-3112.
53. Cagnol S, Van Obberghen-Schilling E, Chambard JC, (2006) Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis 11: 337-346.
54. Liu HF, Hu HC, Chao JI, (2010) Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem Biol Interact 188: 535-545.
55. Hsiao PW, Chang CC, Liu HF, Tsai CM, Chiu TH, et al. (2007) Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol Appl Pharmacol 222: 97-104.
56. Liu BB, Wang WH, (2011) Survivin and pancreatic cancer. World J Clin Oncol 2: 164-168.
57. Bold RJ, Chandra J, McConkey DJ, (1999) Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6: 279-285.
58. Horbinski C, Chu CT, (2005) Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic Biol Med 38: 2-11.
59. Lim PL, Liu J, Go ML, Boelsterli UA, (2008) The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 101: 341-349.
60. Kulich SM, Horbinski C, Patel M, Chu CT, (2007) 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 43: 372-383.
61. Chambers JW, LoGrasso PV, (2011) Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation. J Biol Chem 286: 16052-16062.
62. Nowak G, Clifton GL, Godwin ML, Bakajsova D, (2006) Activation of ERK1/2 pathway mediates oxidant-induced decreases in mitochondrial function in renal cells. Am J Physiol Renal Physiol 291: F840-855.
63. Meloche S, Pouyssegur J, (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239.
64. Cassel JA, McDonnell ME, Velvadapu V, Andrianov V, Reitz AB (2012) Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function. Biochimie.
65. Bose JK, Huang CC, Shen CK, (2011) Regulation of autophagy by neuropathological protein TDP-43. J Biol Chem 286: 44441-44448.
66. Nezis IP, Stenmark H (2012) p62 at the Interface of Autophagy, Oxidative Stress Signaling, and Cancer. Antioxid Redox Signal.
67. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, et al. (2010) A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 30: 3275-3285.
68. Chatzizacharias NA, Giaginis C, Zizi-Serbetzoglou D, Kouraklis GP, Karatzas G, et al. (2010) Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas 39: 930-936.
69. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, et al. (2009) Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8: 125.